$49 per month*
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Pacific Biosciences’ Revenue by Geography, split across Asia pacific, Europe and North America, reported on a quarterly basis from Q1 2016 onwards.
Pacific Biosciences of California aims to build a Genomic analysis system, which will provide the genetic code all living creatures in the most accurate way.
|Geography||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
|Europe (including the Middle East and Africa)||$4.34||$6.49||$6.35||18.20%|
(All figures in millions, except percentages)
In the third quarter of the year 2021, the company collected $34.89 million in revenue. In this quarter, despite having a declining revenue in the Asia Pacific and Europe region, the company saw an overall growth of 13.98% on a quarterly basis, as compared to the previous quarter of Q2 2021, where the revenue stood at the figure of $30.61 million. Comparing the revenue on a year-on-year basis, the company jumped up from $19.08 million in Q3 2020 to $34.89 in Q3 2021, which constituted a significant growth of 82.86%.
After North America, Asia Pacific is the region from which the company generates its second-highest revenue. In the latest quarter of 2021, the Pacific Biosciences collected $9.17 million of revenue from the Asia Pacific region. This constituted 26.3% of the total revenue from all regions in Q3 2021. Asia pacific’s revenue saw a decline of 6.14% in its revenue on a quarter-on-quarter basis, from $9,77 million in Q2 2021. On a year-on-year basis, the revenue witnessed a growth of 58.93%, from $5.77 million in Q3 2020 to $9.17 million in Q3 2021.
Europe (including the Middle East and Africa)
In the latest quarter of 2021, the Pacific Biosciences collected $6.35 million in revenue from the European region, including the Middle East and Africa. This constituted 18.2% of the total revenue from all regions in Q3 2021. Europe’s revenue saw a decline of 2.16% on a quarter-on-quarter basis in its revenue from the last quarter of Q2 2021. In Q2 2021, the revenue was $6.49 million. This was again less than the previous quarter to the extent of 22%. Although from Q3 2020 to Q3 2021, the revenue from the European region made a growth of 46.31% on a year-on-year basis. In Q3 2020, the revenue stood at $4.34 million. Mostly, Europe has been on a decline in generating revenue, although the rate of decline has been decreased in the latest quarter.
The Pacific Biosciences pulls most of its revenues from North America in every quarter. In the latest quarter, the company generated $19.37 million from North America. This constituted 55.5% of the total revenue from all the regions in Q3 2021. As compared to the previous quarter of the year 2021, North America saw a growth of 34.98% on a quarterly basis in its revenue. In Q2 2021, the revenue was $14.35 million. This was 18.01% more than the previous quarter. North America doubled its revenue in Q3 2021 from the same duration of the previous year, i.e., Q3 2020. In Q3 2020, the revenue stood at $8.97 million. It witnessed a significant growth of 115.94% on a yearly basis, the revenues stood at $19.37 million in Q3 2021.
Pacific Biosciences of California was formerly known as Nanofluidics Inc. It was incorporated in the state of Delaware in the year 2000. The company’s executive offices are located at Menlo Park in California. The company has successfully developed Single-molecule real-time (SMRT) sequencing technology by making use of advances in biochemistry, optics, nanofabrications, and more. This powerful technology helps transform the interpretation and understanding of Biological systems through real-time analysis of Biomolecules with single-molecule resolution. The company is listed under the ticker name of PACB in NASDAQ.
Pacific Biosciences renders the longest average read lengths with utmost consensus accuracy and most uniform coverage of each sequencing Biotechnology in the market today by providing the most comprehensive view of epigenomes, transcriptomes, genomes, including the full spectrum of genetic variation. Pacific Biosciences is inclined towards developing high-quality, innovative technology and systems that impact critical areas by directing their efforts to improve the world’s food, energy supply, and diagnosis of diseases. As believed by the Pacific Biosciences, its tools will lead to advance,s generating long-lasting benefits to the entire world and its future.
Did you like Pacific Biosciences’ Revenue by Geography statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.